Clinical Trial Update: Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing once-daily trientine tetrahydrochloride as first-line treatment for Wilson's disease is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wilson Disease

Drugs mentioned

• Trientine tetrahydrochloride (trientine tetrahydrochloride)

Snippet

Sponsor: Orphalan | Conditions: Wilson's Disease | Phase 3 | Status: NOT_YET_RECRUITING